Text Size:AAA

人 VCAM-1 / CD106 蛋白 (His 標籤)

產品資料評論實驗方法
反應性: Human  
應用 : 
  • Slide 1
  • Slide 1
  • Slide 1
100507-T38-50
100507-T38-200
100507-T38-100
50 µg 
200 µg 
100 µg 
Add to Cart
反應性: Human  
應用 : ELISA  
    10113-RP01-400
    10113-RP01-200
    10113-RP01-100
    400 µg 
    200 µg 
    100 µg 
    Add to Cart
    反應性: Human  
    應用 : WB  
    • Slide 1
    10113-T32-50
    10113-T32-200
    10113-T32-100
    50 µg 
    200 µg 
    100 µg 
    Add to Cart
    反應性: Mouse  
    應用 : 
      50163-T16-50
      50163-T16-200
      50163-T16-100
      50 µg 
      200 µg 
      100 µg 
      Add to Cart
      反應性: Mouse  
      應用 : ELISA  
        50163-R130-50
        50163-R130-100
        50 µg 
        100 µg 
        Add to Cart
        反應性: Mouse  
        應用 : ELISA  
          50163-R119-50
          50163-R119-100
          50 µg 
          100 µg 
          Add to Cart
          反應性: Mouse  
          應用 : ELISA  
            50163-RP02-50
            50163-RP02-200
            50163-RP02-100
            50 µg 
            200 µg 
            100 µg 
            Add to Cart
            反應性: Mouse  
            應用 : ELISA  
              50163-RP01-400
              50163-RP01-200
              50163-RP01-100
              400 µg 
              200 µg 
              100 µg 
              Add to Cart

              VCAM1/VCAM-1/CD106 Recombinant ProteinRelated Products

              Related Products

              Featured Reagent Products

              VCAM1/VCAM-1/CD106 protein 研究背景

              Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α4ß7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.

              Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

               VCAM1/VCAM-1/CD106 protein 參考資料
            • Cook-Mills JM. (2002) VCAM-1 signals during lymphocyte migration: role of reactive oxygen species. Mol Immunol. 39(9): 499-508.
            • Preiss DJ, et al. (2007) Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract. 61(4): 697-701.
            • 請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”